Although ligand-induced dimerization was first reported 6 Corresponding author for the epidermal growth factor (EGF) receptor (Yarden and Schlessinger, 1987a,b), the exact mechanism by which E.Tzahar and R.Pinkas-Kramarski contributed equally to this work the monomeric EGF molecule promotes dimerization is still unknown. This is particularly important because the Signaling by epidermal growth factor (EGF)-like three-loop structure of the EGF domain is a common ligands is mediated by an interactive network of four protein motif found in a variety of extracellular proteins, ErbB receptor tyrosine kinases, whose mechanism of including not only growth factors but also adhesion ligand-induced dimerization is unknown. We conmolecules and coagulation factors (Groenen et al., 1994). trasted two existing models: a conformation-driven Moreover, the receptor for EGF (also called ErbB-1) activation of a receptor-intrinsic dimerization site and undergoes extensive heterodimerization with three related a ligand bivalence model. Analysis of a Neu differentimembrane proteins of its subfamily: the orphan receptor ation factor (NDF)-induced heterodimer between ErbB-2 (Goldman et al., 1990; Wada et al., 1990 ) and the ErbB-3 and ErbB-2 favors a bivalence model; the ligand simultaneously binds both ErbB-3 and ErbB-2, two receptors of the Neu differentiation factor (NDF/ but, due to low-affinity of the second binding event, neuregulin), ErbB-3 and ErbB-4 (Tzahar et al., 1994). ligand bivalence drives dimerization only when the NDF itself contains an EGF-like motif that is sufficient receptors are membrane anchored. Results obtained for receptor binding, and it exists in several alternatively with a chimera and isoforms of NDF/neuregulin predict spliced isoforms (Peles and Yarden, 1993) . Although no that each terminus of the ligand molecule contains a known ligand binds directly to ErbB-2, this receptor distinct binding site. The C-terminal low-affinity site appears to serve as a preferred heterodimerizing partner has broad specificity, but it prefers interaction with of the other ErbB molecules (Tzahar et al., 1996) , and ErbB-2, an oncogenic protein acting as a promiscuous the resulting complexes are characterized by relatively low-affinity subunit of the three primary receptors.
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high ligand affinity (Peles et al., 1993; Sliwkowski et al. , Thus, ligand bivalence enables signal diversification 1994) and potent signaling activity (Graus-Porta et al., through selective recruitment of homo-and hetero
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for cellular transformation are also generated by the less active heterodimers such as ErbB-1-ErbB-2 (Kokai et al., Cell growth and differentiation are controlled by soluble 1989; Cohen et al., 1996) and ErbB-1-ErbB-4 (Zhang and membrane-bound polypeptide factors that bind to et al., 1996) . The superior activity of ErbB-2-containing specific cell surface receptors containing a single transheterodimers is apparently due to the ability of ErbB-2 to membrane domain. Ligand-induced oligomerization of decelerate the rate of ligand dissociation, thus prolonging these receptors is essential for transmembrane signaling signaling by all ErbB ligands (Karunagaran et al., 1996) . and, in the case of receptors whose intracellular domains This may be relevant to many clinical observations that carry a protein kinase catalytic activity, either tyrosinecorrelated overexpression of ErbB-2 in human adenospecific or serine/threonine-specific, dimerization is thought carcinomas with poor prognosis (Slamon et al., 1989) , to enable receptor autophosphorylation (Heldin and and to resistance to chemotherapy (Muss et al., 1994) . Ostman, 1996) . This process generates docking sites for cytoplasmic signaling molecules and allows simultaneous Our present work addressed the mechanism of ligand-induced receptor dimerization. Two molecular mechanisms ( Figure 1B ; compare a moderately overexpressing cell line, CB-23M#12, with the CB-23M#1 cell line that were contrasted: according to the first, binding of the monomeric ligand induces a conformational change, overexpresses ErbB-2 to very high levels). This pattern of labeling and the effect of ErbB-2 overexpression similar to the alteration noted in a soluble recombinant ErbB-1 after EGF binding (Greenfield et al., 1989) , and was shared with the full-length ErbB-3 protein that was co-expressed with ErbB-2 ( Figure 1B , compare CB-3 this exposes a cryptic receptor dimerization site. The alternative mechanism assumes that EGF-like ligands are and CB-23 lanes). Therefore, it was concluded that the cytoplasmic portion of ErbB-3 is not necessary for bivalent, and therefore their mechanism of action may be similar to that of the growth hormone. Such a model was ligand-induced homodimerization of ErbB-3, or for heterodimerization with ErbB-2. proposed originally on the basis of the duplicated structure of the ErbB-1's extracellular domain (Gullick, 1994) , and Because soluble forms of receptors for several polypeptide ligands undergo ligand-induced dimerization it received support from two recent lines of evidence: First, affinity labeling using derivatives of EGF indicated (Blechman et al., 1995) , we constructed a peptide-tagged soluble ErbB-3 (denoted TAG-3, Figure 1A ) and examined that the N-terminal tail of this ligand binds to the Nterminal subdomain of its receptor, whereas the C-terminal its ability to form dimers. Affinity labeling experiments failed to detect homodimers of the soluble form of ErbB-3, tail of EGF juxtaposes to subdomain III of ErbB-1 (Summerfield et al., 1996) . Second, comprehensive anaalthough this protein retained relatively high affinity for NDF ( Figure 1C and data not shown). A similar soluble lysis of a soluble version of ErbB-1 in highly concentrated solutions indicated prevalence of a 2:2 ligand-receptor version of ErbB-4 (TAG-4) also displayed no dimer formation in solution, even at high ligand concentrations complex (Lemmon et al., 1997) .
By concentrating on the apparently most stable hetero-( Figure 1C ). To examine ligand-induced heterodimerization of the soluble proteins, we used a tagged extracellular dimers between the kinase-deficient ErbB-3 and the ligandless receptor, ErbB-2, we present evidence in favor of an domain of ErbB-2 (TAG-2) and a fusion protein containing the whole extracellular domain of ErbB-3 linked to the asymmetric bivalence model. The use of tagged deletion mutants of ErbB-3 implied that receptor dimerization may catalytic portion of the human placental alkaline phosphatase (AP). This protein, HAP-3 (Tzahar et al., 1994) , binds not be attributed to an intrinsic dimerization site, but that it depends on membrane anchorage. Biophysical, with high affinity to NDF and enables a highly sensitive co-immunoprecipitation assay by using the enzymatic AP biochemical and immunological approaches indicated simultaneous binding of NDF to ErbB-3 and ErbB-2.
activity. However, we could not detect complex formation between HAP-3 and the soluble ErbB-2, in the form of Lastly, cooperativity of the two binding sites was demonstrated by using a chimeric EGF-NDF molecule that also TAG-2, when using a co-immunoprecipitation assay with anti-ErbB-2 antibodies in conjunction with either affinity identified the N-terminal portion of NDF as the high affinity site. A second, low-affinity site located at the labeling ( Figure 1C ) or an AP enzymatic assay (data not shown). Similarly, an AP fusion protein of ErbB-4 (HAP-4) C-terminus appears to determine the identity of the homoor heterodimeric partner of the primary receptor.
displayed no detectable interaction with a soluble ErbB-2 ( Figure 1C ). Since the AP portion conferred some spontaneous dimerization on the HAP proteins (right two lanes
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in Figure 1C ), which may interfere with ligand-induced dimer formation, we also performed a co-immunoprecipitMembrane anchorage is necessary and sufficient for ligand-induced receptor dimerization ation assay using two tagged proteins (TAG-2 with either TAG-3 or TAG-4) and monoclonal antibodies (mAbs) that To study the mechanism of receptor dimerization, we selected the most prevalent inter-ErbB interaction between are strictly specific for each ErbB protein Klapper et al., 1997) . No evidence for NDFErbB-3 and ErbB-2 (Tzahar et al., 1996) , and used affinity labeling to follow dimer formation. The possibility that dependent heterodimerization of ErbB-2 with either a soluble ErbB-3 or a soluble ErbB-4 was observed in this the cytoplasmic domain of ErbB-3 contributes to ligandinduced dimerization by providing a dimerization site was assay ( Figure 1C ), indicating that the transmembrane domain of each NDF receptor is essential for both homoexamined by constructing a deletion mutant in which the whole intracellular portion was replaced by a short Myc and heterodimer formation by NDF. This conclusion is consistent with biophysical studies that failed to detect peptide tag. This protein, ErbB-3M ( Figure 1A ), was expressed in Chinese hamster ovary (CHO) cells, either dimerization of other forms of soluble NDF receptors (Horan et al., 1995) , and contrasts with most other growth alone (CB-3M cells) or in combination with an ectopically expressed human ErbB-2 (CB-23M cells). Covalent crossfactor receptors whose ligand-dependent dimerization in solution was analyzed. linking of radiolabeled NDF to the surface of CB-3M cells detected a major monomeric receptor band that Considering the ability of a transmembrane mutation in the rodent homolog of ErbB-2 to induce constitutive underwent labeling, and a higher molecular weight dimeric species ( Figure 1B) . The lower form represents primarily homodimerization (Weiner et al., 1989) , the possibility that the transmembrane domain of ErbB-3 acts as an ErbB-3 monomers (see below). Because of the following reasons, we assume that the dimeric form includes, in intrinsic dimerization site was appealing. However, because NDF-induced receptor dimerization displays strict addition to homodimers, a covalently held heterodimer between ErbB-3 and the endogenous ErbB-2 of CHO specificity to ErbB proteins (Tzahar et al., 1996) , this model predicts that the hydrophobic transmembrane stretch cells: first, it underwent immunoprecipitation with ErbB-2-specific antibodies (data not shown) and second, its relative of ErbB-3 may not be replaced with another transmembrane sequence without affecting receptor dimerization. labeling was proportional to the level of ErbB-2 expression In order to test this prediction, we constructed a truncation affinity labeling with NDF clearly indicated that the mutated receptor retained the ability to undergo dimerization. mutant of ErbB-3, whose transmembrane domain was replaced with the corresponding stretch of the fibroblast Co-immunoprecipitation experiments with antibodies to ErbB-2 implied that heterodimerization with this receptor growth factor receptor 3 (FGFR-3). Upon expression in CHO cells, this mutant, ErbB-3MF ( Figure 1A ), was occurred, but at relatively low efficiency compared with an identical protein whose transmembrane domain was expressed correctly at the cell surface and conferred specific binding of NDF (data not shown). However, derived from ErbB-3 (ErbB-3M, Figure 1D ). It is worth noting that the extent of co-immunoprecipitation of ErbB-3 with ErbB-2 displayed variation in our experiments, but were incubated at 22°C with a radiolabeled NDF-β1 (10 ng/ml), followed by covalent cross-linking with BS 3 (1 mM). Alternatively, the various indicated combinations of the soluble receptors were coincubated with the ligand. The mixtures of recombinant proteins were then subjected to immunoprecipitation (I.P.) with mAbs specific for the indicated ErbB proteins, followed by gel electrophoresis and autoradiography. To assay the presence of TAG-2 in the respective conditioned medium, it was subjected to immunoblotting (I.B.) with an antibody to ErbB-2 (right panel). Note that the AP fusion protein displays monomers and dimers of receptor-ligand complexes due to spontaneous dimer formation by the AP portion, but neither homo-nor heterodimers of TAG proteins are detectable by affinity labeling or by co-immunoprecipitation. (D) Dimerization of the ErbB-3MF mutant. The transmembrane mutant of ErbB-3 was expressed in CHO cells (CB-3MF cells), and its ability to undergo dimerization was followed by affinity labeling as in (A), except that immunoprecipitation (I.P.) was performed subsequently with antibodies to either ErbB-2 or ErbB-3, as indicated. As control, we used CB-3M cells expressing a similar truncation mutant but with the endogenous transmembrane domain of ErbB-3. (E) Dimerization of the ErbB-3GPI mutant. Cells expressing ErbB-3GPI either alone (CB-3GPI cells) or in the presence of an overexpressed ErbB-2 (CB-23GPI cells, two clones), or CB-3M cells for control, were subjected to affinity labeling with [ 125 I]NDF-β1. The left panel shows sensitivity of the GPI tail to enzymatic cleavage. Prior to covalent cross-linking of the ligand-receptor complexes, the cells were either treated (4 h at 37°C) with PI-PLC (lanes marked ϩ) or they were left untreated. Following covalent cross-linking, cells were solubilized and the lysates directly resolved by gel electrophoresis. The other panels show the results of a similar analysis, except that no PI-PLC treatment was performed, and cell lysates were subjected to immunoprecipitation (I.P.) with antibodies to the indicated ErbB proteins, prior to gel electrophoresis.
this proposition. A GPI-anchoring motif was fused to the ErbB-2 is a shared low-affinity receptor of EGF-like ligands C-terminal tail of the extracellular domain of ErbB-3, and An alternative to the existence of an intrinsic receptor the mutant protein, ErbB-3GPI ( Figure 1A ), was expressed dimerization site is the proposition that receptor dimerizin CHO cells. Control experiments confirmed that the ation is driven by ligand bivalency. When applied to ErbB-3GPI protein was expressed at the cell surface and ErbB-2, a protein that functions as a preferred heterobound NDF in a specific manner. Evidently, it also dimeric partner of all ErbB proteins (Tzahar et al., 1996) , underwent covalent linkage to a GPI tail, because we could a bivalent model predicts direct low-affinity binding of cleave the lipid-anchored mutant, but not a transmembrane EGF-like ligands, including NDF, to ErbB-2. This possiversion of ErbB-3, with a phosphatidylinositol-specific bility was implied by a previous study that documented phospholipase (PI-PLC; Figure 1E ). Affinity labeling the ability of ErbB-2 to increase affinity labeling of a experiments similar to those performed with other mutants 180 kDa protein by NDF/heregulin (Sliwkowski et al., of ErbB-3 readily detected homodimers of the ErbB-3GPI 1994) but, due to the similar molecular weights of ErbB-3 mutant ( Figure 1E ). However, similarly to ErbB-3MF, and ErbB-2, and stable associations between the two heterodimerization with ErbB-2 was limited compared proteins, the identity of the labeled 180 kDa protein with that of a full-length ErbB-3 ( Figure 2A ) or its remained unclear (Peles et al., 1993; Sliwkowski et al., truncated mutant, ErbB-3M. To verify heterodimer form-1994; Tzahar et al., 1996) . The availability of ErbB-3M, ation between ErbB-2 and an ErbB-3 protein that lacks a a truncation mutant of ErbB-3, allowed us to address transmembrane domain, we stably co-overexpressed the direct binding of NDF to ErbB-2. Covalent cross-linking two proteins in CHO cells. Analysis of two clones of the of cells expressing ErbB-3M with a radioactive NDF resulting cell line, CB-23GPI, showed that immunomolecule labeled two dimeric species that were identified precipitates of ErbB-2 contained both monomeric and immunologically as homodimers of the truncation mutant dimeric forms of the affinity-labeled ErbB-3GPI ( Figure  and ErbB-3M-ErbB-2 heterodimers ( Figure 2A ). How-1E), indicating heterodimer formation and dependency ever, monomeric ErbB-3M, but no monomer of ErbB-2, on ErbB-2 overexpression. Taken together, the results was labeled in cells whose expression of exogenous presented in Figure 1 reveal that NDF-induced homodimerization of ErbB-3, and to some extent heterodimerization with ErbB-2, is independent of a specific receptor domain, including the transmembrane stretch, but it strictly depends on membrane anchorage. By inference, our data weaken the possibility that ligand-induced ErbB dimerization is mediated by a dimerization site intrinsic to the receptor molecule. Figure 1A , except that in order to increase its efficiency, covalent cross-linking was performed after scraping of the cells into Eppendorf tubes. Cell lysates were subjected to immunoprecipitation (I.P.) with antibodies to ErbB-2 or to ErbB-3, as indicated. Monomeric (closed arrowheads) and dimeric (open arrowheads) forms of ErbB-3 are indicated. Note that homo-and heterodimers of ErbB-3 could be resolved, but the endogenous hamster ErbB-2 was not recognized by our human-specific mAbs. The presumed monomeric form of ErbB-2 (185 kDa) that underwent affinity labeling is marked by a closed arrowhead. (B) Acceleration of NDF dissociation by a monovalent fragment of an antibody to ErbB-2. CHO cells that co-overexpress ErbB-2 and ErbB-3 (CB-23 cells) were first incubated for 2 h at 4°C with a radiolabeled NDF (1 ng/ml). Thereafter, the ligand was removed and the cells incubated with an unlabeled ligand (400 ng/ml), either alone (j) or in the presence of a monovalent Fab fragment (20 μg/ml) of one of the mAbs to ErbB-2: L431 (n) or L26 (s). Cell-bound radioactivity as well as that released to the medium were then determined and described as a function of time of incubation at 4°C. The results are expressed as the ratio between the amount of ligand that was bound at time t (B t ) and the initially bound ligand (B o ), and they represent the average of duplicates. The experiment was repeated twice. (C) Affinity labeling of ErbB receptorbodies with radiolabeled EGF was performed as follows. Equal amounts of fusion proteins between the Fc portion of human IgG 1 and the indicated ErbB proteins (IgB-1 to 4) were incubated with radiolabeled EGF at 50 ng/ml for 2 h at 22°C. Crosslinking reagent was then added for an additional 1 h. Thereafter, the complexes were adsorbed on protein A-containing Sepharose beads, washed extensively and resolved by gel electrophoresis under reducing conditions. For control of the specificity of IgB-2 interaction with a radiolabeled EGF, we incubated IgB-2 with a 100-fold excess (EX.) of an unlabeled EGF.
ErbB-2 was moderate (clone 12 of CB23M). Nevertheless, , 1997) , but left open the possibility that type II antibodies inhibit heterodimer formation because of their specificity of these weak interactions was verified by using a control immobilized ligand [interferon-γ (IFN-γ)] and bulky structure or due to depletion of the available ErbB-2 by means of antibody-induced homodimerization. To conseveral unrelated IgG-fused receptors (data not shown).
The calculated affinity of ErbB-2 for NDF was 0.85 μM, trast these alternative models with the possibility that ErbB-2 contains an intrinsic ligand-binding site, we tested unlike the 10 -9 M values that were displayed by the direct receptors, ErbB-4 and ErbB-3. This 1000-fold affinity the effect of a monovalent fragment of a type II mAb, denoted L26, in comparison with a control antibody to difference is in agreement with previous experiments that used light scattering and sedimentation equilibrium to ErbB-2, L431. As shown in Figure 2B , the Fab fragment of L26, but not Fab-L431, increased the rate of NDF measure NDF affinity for different forms of soluble ErbB-3 and ErbB-2 (Horan et al., 1995) . Binding of NDF to dissociation from CB-23 cells. Similar results were observed when EGF dissociation from ErbB-1-expressing ErbB-1, although detectable by the Biacore analysis (Table  I) , has not been reported previously, probably because it cells was examined (data not shown), implying that both ligands bind directly to ErbB-2.
is the weakest interaction. Taken together, the results presented in Table I and previous biophysical measureDirect ligand binding to ErbB-2 was confirmed independently by in vitro experiments using purified preparments (Horan et al., 1995) indicate that NDF binds directly, but with low affinity, to ErbB-2. This conclusion is in line ations of a recombinant soluble ErbB-2 protein, in conjunction with real-time kinetic measurements or affinity with the observed very weak affinity labeling of ErbB-2 (Figure 2A ), and it is consistent with our interpretation of labeling. NDF-β1 was covalently immobilized to dextran fibers of a Biacore (Pharmacia) flow cell, and the kinetics the ability of certain ErbB-2-specific mAbs to accelerate the ligand dissociation rate ( Figure 2B ). of interaction with a soluble ErbB-2 derivative were studied by measuring changes in surface plasmon reson-
The possibility that heterodimerization of EGF and NDF receptors with ErbB-2 is driven by direct interactions ance of an underlying gold film (in resonance units, RU) (Johnson et al., 1991) . The soluble ErbB-2 derivative, a of the latter with either ligand predicts that the binding site of ErbB-2 can recognize several, if not all, EGF-like fusion protein between the extracellular domain of ErbB-2 and the Fc portion of human IgG 1 (denoted IgB-2) (Chen ligands. To examine this prediction, we tried to immobilize EGF to the dextran matrix of the Biacore cell. However, et al., 1996) , was injected at various concentrations into the flow cell and kinetic constants calculated by using due to the relatively low pI of EGF and the presence of only one amino group available for coupling, the signals Biacore Incorporated software. As controls, we performed the same analysis with similar IgG fusion versions of the we recorded were much weaker than those obtained with NDF (data not shown). Therefore, we examined EGF other three ErbB proteins (receptorbodies). A summary of the results is shown in Table I . As expected, soluble forms binding to ErbB-2 by using affinity labeling with [ 125 I]EGF ( Figure 2C ). The soluble form of ErbB-2 recognized EGF of the two direct NDF receptors (IgB-3 and IgB-4) displayed similar rapid on rates and slow off rates when in a specific manner, as indicated by the ability of high concentrations of the unlabeled ligand to displace analyzed on an immobilized NDF, yielding K D values that are consistent with previously determined parameters for [ 125 I]EGF ( Figure 2C , left panel). In addition, no affinity labeling was observed when non-ErbB receptorbodies soluble or membrane-bound receptors (Tzahar et al., 1994) . However, NDF also interacted, albeit weakly, with were tested with a radiolabeled EGF (data not shown). Due to the dimeric structure of the soluble ErbB-2 receptora soluble ErbB-2, as well as with a soluble ErbB-1 (Table  I) . Whereas both receptors associated with the immobilized body that is held by disulfide bridges, both monomers and dimers were labeled by EGF. Interestingly, the soluble ligand at a similar rate, that was~50-fold slower than that forms of both ErbB-3 and ErbB-4 also underwent affinity labeling by a radiolabeled EGF, and this was abolished by an excess of the unlabeled ligand ( Figure 2C , and data not shown). The observed cross-specificity was not unique to EGF, because another ligand of ErbB-1, namely the heparin-binding EGF-like growth factor (HB-EGF), also underwent covalent cross-linking to the two NDF receptors, as well as to ErbB-2 (data not shown). Taken together, our results confirm the prediction that ErbB-2 has a ligandbinding site that specifically recognizes several EGF-like ligands. Unexpectedly, weak binding promiscuity is shared by other members of the ErbB family. Thus, in addition to the strong interaction of ErbB-1 with both EGF and HB-EGF, the former ligand weakly interacts with ErbB-3 and ErbB-4 ( Figure 2C ), and HB-EGF binds to ErbB-4 better than to ErbB-3 (data not shown). Likewise, NDF interacts with high affinity with both ErbB-3 and ErbB-4, but it recognizes ErbB-1 with very low affinity (Table I ).
Cooperative and specific interaction of biregulin with an ErbB-2-ErbB-3 heterodimer For the ErbB-2-ErbB-3 heterodimer, our results are com- NDF receptors (Barbacci et al., 1995) . This finding is reminiscent of the emerging promiscuity of ligand-receptor interactions in the ErbB family, and it prompted us to and specific binding of biregulin ( Figure 3A ; K D ϭ 2 nM, B max ϭ 33 pM). Because 32D sublines expressing ErbB-4 analyze the exact receptor specificity of biregulin.
A series of interleukin 3 (IL-3)-dependent 32D myeloid combinations are relatively unstable, we concentrated on ErbB-3 combinations. The remarkable cooperative effect cells that express individual ErbB receptors or their combinations (Pinkas-Kramarski et al., 1996a) was used of co-expressed ErbB-2 and ErbB-3, and the observed residual binding to D3 cells, implied that failure to detect to determine biregulin specificity. These cells offer the advantage of receptor analysis in the absence of crosssignificant binding to a singly expressed ErbB-3 may be due to the long washing procedure of the suspensiontalk, because parental 32D cells express no known ErbB molecule. Saturation curves of the binding of a radiogrown 32D cells. As an alternative, we used a ligand displacement assay, which is more suitable for analysis of labeled biregulin to cells expressing either ErbB-2 alone (D2 cells), ErbB-3 alone (D3 cells) or only ErbB-4 (D4 low-affinity interactions. The results obtained in this assay indicated that biregulin is practically equipotent to EGF cells) indicated no binding to D2 cells (data not shown) and very low binding to the latter two cell lines (Figure in binding to ErbB-1 ( Figure 3B , upper panel), and to NDF-β1 in binding to cells co-expressing ErbB-2 and 3A). By contrast, cells that simultaneously expressed ErbB-2 and ErbB-3 (D23 cells) displayed relatively high ErbB-3 ( Figure 3B , lower panel). However, the chimeric ligand displayed a 10-fold lower apparent affinity, compared with NDF-β1, towards cells expressing ErbB-3 alone ( Figure 3B , middle panel) or ErbB-4 alone (data not shown). Consistent with the observed interaction between a soluble form of ErbB-3 and EGF ( Figure 2C ), high concentrations of this ligand were able to displace NDF from ErbB-3-expressing cells ( Figure 3B , middle panel). However, due to the ability of ErbB-2 to enhance binding of NDF to ErbB-3 (Sliwkowski et al., 1994) , EGF could displace NDF from D23 cells only at extremely high concentrations ( Figure 3B , lower panel). Affinity labeling experiments were unable to detect the low-affinity interaction of biregulin with either ErbB-3 or ErbB-4, and also confirmed lack of significant interaction with ErbB-2-expressing cells ( Figure 3C ). As expected, cells coexpressing the two proteins displayed intense labeling by biregulin, in line with cooperative ligand binding. Interestingly, in D23 cells, unlike in other cell lines, biregulin labeled primarily a dimeric form, most likely an ErbB-3-ErbB-2 heterodimer. In terms of the bivalence model, biregulin appears to bind with low affinity to ErbB-3, possibly through site 1, and its cooperative binding to cells co-expressing ErbB-2 is mediated by site 2 interactions with the membrane-immobilized co-receptor. The cellular activities of biregulin were consistent with a specific cooperative effect of ErbB-2 and ErbB-3. Biregulin could strongly stimulate tyrosine phosphorylation of ErbB-1, along with other substrates, when this receptor was singly expressed, whereas neither ErbB-3 nor ErbB-2 were phosphorylated by this ligand when expressed alone ( Figure 4A ). Control experiments verified ErbB-2 phosphorylation by specific mAbs (data not shown), whereas ErbB-3 could not be activated when expressed alone, due to its defective kinase domain (Guy et al., 1994) . Remarkably, biregulin induced a strong kinase stimulatory effect in cells co-expressing ErbB-2 and ErbB-3 (D23 cells). Likewise, in D13 cells that coexpress ErbB-1 and ErbB-3, NDF, but not biregulin or EGF, induced phosphorylation of ErbB-3 in addition to ErbB-1 (ErbB-3 is the higher band in Figure 4A , D13 panel). Thus, the modified N-terminus of biregulin may and therefore biregulin acts like EGF on D13 cells. In were incubated for 1 h in the absence of serum factors and IL-3, and line with our observations of cross-reactivity of EGF with then treated for 10 min at 37°C with or without EGF, NDF-β1 or ErbB-3, this ligand induced a small but reproducible biregulin, each at 100 ng/ml. Whole-cell lysates were prepared, cleared of cell debris and nuclei, and subjected to Western blotting with an kinase stimulatory effect in D23 cells ( Figure 4A ). effect on tyrosine phosphorylation in these cells, but the cooperative effect of biregulin was much stronger in both kinase and proliferation assays.
N-terminal five amino acids of NDF can confer specific recognition of ErbB-3, but the presence of ErbB-2 greatly In conclusion, cooperativity between ErbB-3 and ErbB-2 could be demonstrated in both ligand-binding enhances binding. Because we have shown previously that the C-terminal portion of NDF is responsible for analyses and biological assays. This implies that the differential recruitment of a heterodimeric partner to ErbBmodel. The cooperative binding of EGF (Wada et al., 3 (Pinkas-Kramarski, 1996b) , the observed cooperative 1990), NDF (Peles et al., 1993; Sliwkowski et al., 1994 ) effect of biregulin suggests that the primary receptorand biregulin (Figure 3 ) to cells co-overexpressing a binding site of NDF maps to the N-terminal part of the primary receptor together with ErbB-2 is explained molecule, whereas the putative low-affinity binding site similarly by direct binding of the co-receptor to the low-(site 2) is confined to the C-terminal portion. affinity site of either ligand. Likewise, the observation that prevention of ErbB-2 expression at the cell surface accelerates the rates of dissociation of both NDF and
Discussion
EGF (Karunagaran et al., 1996) is reasoned by the The ErbB family of growth factor receptors is a prototype inaccessibility of ErbB-2 to the low-affinity sites of the for an interactive signaling system that diversifies bioligands. Another interesting observation explained by the logical signals by means of combinatorial ligand-receptormodel is the unexpected displacement of a cell-bound effector complexes .
EGF by NDF, and its dependency on ErbB-2 (Karunagaran Binding of any of the multiple ErbB ligands sets this et al., 1995) . system in motion by means of ligand-induced receptor
The bivalence model raises an important question, dimerization processes, whose exact mechanism has not namely: why were we ( Figure 1C ) and others (Horan been addressed before. Previous biophysical analyses of et al., 1995) unable to detect NDF-induced dimers in EGF binding to ErbB-1 (Greenfield et al., 1989) and solution, although the ligand is bivalent? We note that examination of the stoichiometry of this interaction (Weber soluble forms of most other receptors undergo oligomerizet al., 1984) suggested that one ligand molecule binds to ation in solution. Examples are the receptors for growth one receptor molecule, whose conformation is changed in hormone (Cunningham et al., 1991) and stem cell factor favor of promoting receptor dimerization. However, (Lev et al., 1992) . However, in these and other cases, the several different models questioned this scenario and affinities of the two receptor-binding sites of the ligands proposed a theoretical 1:2 or 2:2 stoichiometry of ligandare similar and relatively high. This contrasts with NDF: receptor interactions that implies bivalence of the EGFwhereas the affinity of site 1 of this ligand is similar to like motif (Gullick, 1994; Lemmon and Schlessinger, that of other factors, the affinity of site 2 (as reflected by 1994; Heldin and Ostman, 1996) . Our present study, binding to ErbB-2) is two or three orders of magnitude that relates primarily to NDF and an ErbB-3-ErbB-2 lower (Table I ) (Horan et al., 1995) . Apparently, this very heterodimer, provides an experimental support for such low affinity cannot promote receptor dimerization in models.
solution. However, the necessity for membrane tethering for homo-and heterodimerization of ErbB-3 (Figure 1) A sequential ligand-induced receptor dimerization implies that ligand immobilization augments binding to process site 2. Obviously, binding to site 1 involves diffusion in On the basis of simultaneous binding of NDF-β1 to both three dimensions, but association with site 2 is guided by ErbB-3 and ErbB-2 (Figure 2A) , detection of direct ligand the two-dimensional membrane plane. Presumably, the binding to a soluble form of ErbB-2 (Table I and Figure  restricted translational diffusion of the initial binary com-2C) (Horan et al., 1995) and the ability of a monovalent plex, together with possible constraints on rotational fragment of an mAb to the putative binding site of diffusion and a ligand steering effect, provide a geometric ErbB-2 to dissociate NDF-receptor complexes (Figure factor (Northrup and Erickson, 1992 ) that compensates 2B) (Klapper et al., 1997) , we favor the possibility for the intrinsically low affinity of site 2. It follows that that NDF is a bivalent ligand which promotes receptor at very high concentrations, ligand-induced dimerization dimerization through a sequential process. According to of ErbB proteins may be detectable in solution. Indeed, this model, NDF first binds to the primary receptor when Ͼ10 -6 M concentrations of a soluble form of ErbB-1 (ErbB-3) through its high affinity and highly selective site were incubated with EGF in solution, ligand-induced (site 1). This anchors the ligand to the cell surface and oligomerization was detectable (Hurwitz et al., 1991) . facilitates binding of a second receptor to a putative lowaffinity site of NDF (site 2). Because the affinity of this Locations of the two receptor-binding sites of NDF site is extremely low (Table I) , its occupation must be Structural and functional (Barbacci et al., 1995;  Pinkaspreceded by ligand immobilization by the membraneKramarski et al., 1996b) information on NDF, together anchored primary receptor (Figure 1) .
with our results with biregulin ( Figures 3 and 4) and the The sequential model explains several previous observwealth of mutational data on EGF and transforming growth ations. For example, pre-formed receptor dimers are factor-α (TGF-α) (Groenen et al., 1994) , already allow sensitive to the same conditions that break ligand-receptor assignment of specific residues to the two putative sites complexes (Yarden and Schlessinger, 1987b) , implying of NDF. The solution structure of NDF, as revealed by that the ligand physically holds the receptors in dimers, two- (Nagata et al., 1994) and three-dimensional nuclear rather than inducing a stabilizing conformational change. magnetic resonance (NMR) (Jacobsen et al., 1996) , preThe higher stability of bivalent interactions, as opposed dicts two slightly overlapping structural motifs comprising to monovalent binding, explains why receptor homodimers an N-terminal three-stranded β-sheet and a small bind their ligands at higher affinity than the corresponding C-terminal two-stranded β-sheet ( Figure 5 ). The following monomeric forms (Ben-Levy et al., 1992; Zhou et al., considerations led us to propose that the free terminus of 1993). In addition, the fact that ErbB proteins interact each of these two domains functions as a distinct binding extensively among themselves but do not complex with other receptors is explained readily by the bivalence site (blue and red clusters in Figure 5 ). A model structure of the EGF-like motif of NDF-β was predicted by using the average NMR structure of NDF-α (entry 1HRE, Protein Data Bank) and a homology program (Biosym/MSI, San Diego, CA). Only residues 1-50 of NDF-β (corresponding to residues 177-226 of the full-length molecule) are shown, with the N-and the C-terminus pointing to the bottom and top of the figure, respectively. The left part is a space-filling representation of the solvent-accessible structure calculated with a 1.4 Å probe. The right part is the corresponding ribbon diagram highlighting the five β-strands (arrows), an α-helical domain and the three disulfide bridges (green). The proposed locations of the two putative receptor-binding sites (blue and red residues) and their hydrophobic core amino acids (marked in yellow) are shown. The conserved arginine residue (R44) that stabilizes the relative orientation of the two β-sheets is marked only in the left part.
Site 1. Because the five N-terminal amino acids of NDF favor the possibility that the former cluster is involved in conferred to an EGF molecule the ability to recognize and receptor binding, because the hydrophilic tail (Ser1 and activate ErbB-3 (Figures 3 and 4) , and because no other His2) packs against it (blue residues in Figure 5 ), and portion of NDF, when grafted into EGF, had a comparable because mutational replacement of Ile23 in EGF, the effect (Barbacci et al., 1995) , we assume that the major homolog of Val23 in NDF, suggested that this residue determinant of NDF binding resides at its N-terminus. binds directly to a hydrophobic pocket of ErbB-1 (Koide This assignment was predicted by NMR studies on the et al., 1992). basis of comparison of the tertiary structure of NDF with Site 2. Because isoforms α and β of NDF share high those of EGF and TGF-α (Jacobsen et al., 1996) . The affinity binding to ErbB-3 (through site 1) but differ in N-terminal residues 2-6 of NDF form a well-defined heterodimer formation (Pinkas-Kramarski et al., 1996b) , β-strand, rather than being disordered as found in EGF.
the bivalence model predicts that site 2 is confined to the Deletion of the first two amino acids of NDF severely variable portion of the two isoforms. Out of the 50 amino reduced binding of biregulin to NDF receptors, whereas acids necessary for NDF binding, only nine residues differ individual replacements of either one of the next three between the two isoforms, and five of them are clustered residues did not impair receptor binding (Barbacci et al., in the C-terminus of the EGF-like motif. For several 1995). Leu3 and Val4 of NDF are involved in hydrogen reasons it seems that the most C-terminal two hydrophobic bonding with Met22 and in hydrophobic interactions with residues (Val49 and Pro50 in NDF-α and Val49 and Met50 β-strand II, especially residues Phe21, Met22 and Val23 in NDF-β) comprise the core of this site (red residues in (Jacobsen et al., 1996) . As a result of these interactions, Figure 5 ). Some of us have previously reported that two hydrophobic clusters are formed on opposite faces of deletion of this pair of residues in NDF-α, or only the NDF molecule: Leu3, Phe21, Val23 and Leu33 on one side and Val4, Met22 and Tyr32 on the other side. We the most C-terminal amino acid of NDF-β, dramatically impaired, but did not abolish, receptor binding (Barbacci to trans-phosphorylate other ErbB molecules and potency of biological signals (Kramer et al., 1994; Beerli and et al., 1995) . Nevertheless, substitution of Pro50 with leucine did not significantly affect receptor binding, implyHynes, 1996) . ing that a hydrophobic side chain is important, but not its exact identity. Substitutions of several hydrophobic Is the oncogenic role of ErbB-2 related to its residues in the C-terminal domain of EGF and TGF-α ligand-binding promiscuity? reduced receptor binding, with the most significant Ectopic overexpression of ErbB-2, but not other members decrease observed upon mutagenesis of the highly conof its family, in cultured cells is sufficient to confer a served Leu47, the homolog of Pro50/Met50 in NDF transformed phenotype (Di Fiore et al., 1987; Hudziak molecules (Groenen et al., 1994) . It is therefore likely et al., 1987) , and amplification of the gene in several that residues 49 and 50 of NDFs are the major structural types of human adenocarcinomas is correlated with short determinants of site 2. patient survival time (Stancovski et al., 1994) . The superior Figure 5 provides a three-dimensional representation of oncogenic action of ErbB-2 may be due to the existence of the proposed NDF-binding sites. Obviously, in addition to a direct ErbB-2 ligand, which is not yet fully characterized the indicated residues, other amino acids, whose identities (Samanta et al., 1994) , or it may result from a relatively remain open, contribute to ligand binding. Nevertheless, high basal catalytic activity (Lonardo et al., 1990) . Alternit is remarkable that the predicted sites are remote from atively, because ErbB-2 emerges from this study as a loweach other in the folded protein, and their cores are affinity receptor of EGF-like ligands whose function is characterized by high surface hydrophobicity (Nagata analogous to that of shared subunits of lymphokine or et Jacobsen et al., 1996) . The available functional neurotrophin receptors, its role in oncogenesis may be and structural data suggest that the intervening sequence due to amplification of growth factor signaling. Consistent may not interact directly with the primary or secondary with trans-activation of other ErbB receptors, rather than receptors. Perhaps the most important residue is Arg44 an autonomous signaling function, targeted inactivation (Arg41 in EGF, marked in the left panel of Figure 5 ), of erbB-2 in mice resulted only in phenotypic traits that which lies in the interface between the two domains of are shared by mice lacking other ErbB proteins and ligands NDF and forms three hydrogen bonds with the N-terminal (Lee et al., 1995) . The proposed bivalence model predicts domain. In line with a purely structural role, it is conserved that excessive presence of ErbB-2 can force formation of in all ErbB ligands, from Caenorhabditis elegans to ErbB-2-containing heterodimers. Since signaling by this human. In addition, its mutagenesis in EGF and TGF-α type of dimer is enhanced and prolonged relative to demonstrated an absolute requirement for receptor binding, other receptor combinations (Graus-Porta et al., 1995 ; probably due to structural distortion. We propose, there- Karunagaran et al., 1996) , ErbB-2 overexpression is fore, that the core of the EGF-like motif, at least in the expected to confer a clonal selective advantage in cancer case of NDF, is critical only for maintaining the appropriate progression. Possibly, an increased responsiveness to the orientation and distance between the two most distally many stroma-derived EGF-like growth factors is the located binding sites. mechanism underlying several laboratory and clinical observations that correlated ErbB-2 overexpression with Multiplicity of ErbB ligands loss of dependency on steroid hormones, increased sensitIt is worthwhile addressing the relevance of the bivalence ivity to radio-and chemotherapy and enhanced metastatic model to the nine known ErbB-1-specific ligands, especipotential. On the other hand, inhibition of tumor growth ally because it is currently unknown how these distinct in animal model systems and in clinical trials (Baselga ligands can elicit different biological responses although et al., 1996) by using mAbs specific to the extracellular they bind to the same receptor. The existence of heterodomain of ErbB-2 is probably due to functional inactivdimers between ErbB-1 and other ErbB molecules, and ation of the oncogenic protein. This may proceed either demonstration of direct binding of EGF and HB-EGF to by accelerating an endocytic removal of ErbB-2 from the ErbB-2 ( Figure 2C , and data not shown), imply that cell surface or by inhibiting ErbB-2 interaction with ErbB-1-specific ligands are indeed bivalent. Also supportactivated growth factor receptors (Klapper et al., 1997) . ive are three independent lines of evidence. First, monoThe latter mechanism is mediated by binding of the specific antibodies to EGF identified two non-overlapping antibody to the putative low affinity and promiscuous regions within the EGF molecule (residues 22-32 and 33-ligand-binding site of ErbB-2. Therefore, molecular 53) as essential for receptor binding (Katsuura and Tanaka, definition of this site may identify a new target for cancer 1989). Likewise, by using heptapeptides that encompass therapeutic drugs. the whole sequence of TGF-α, two groups of ligandinhibitory peptides were identified (residues 22-34 and 36-50) (Richter et al., 1992) . Third, analysis of single-
Materials and methods
and double-site mutants (Campion et al., 1993) identified Materials and antibodies specific residues within these two groups as necessary for EGF and HB-EGF (human, recombinant) were purchased from R&D receptor recognition (Groenen et al., 1994) . Thus, in  analogy to the two types of NDF isoforms, ErbB-1-specific residues 177-246) was from Amgen (Thousand Oaks, CA). The chimeric biregulin molecule, comprising the five most N-terminal amino acids of ligands may share site 1 but differ in site 2. Consequently, NDF/heregulin (amino acids 177-181) connected to EGF (amino acids each ligand may stabilize different heterodimers of ErbB-1, 6-48) was synthesized as previously described (Barbacci et al., 1995) . and thereby recruit a unique signal transduction pathway.
Radioactive materials were from Amersham (Buckinghamshire, UK).
Potentially, this mechanism may account for the observIodogen and bis(sulfosuccinimidyl) suberate (BS 3 ) were from Pierce. mAbs to ErbB proteins were used for immunoprecipitations that ErbB-1 ligands differ in cellular affinity, ability ation experiments, whereas polyclonal antibodies against the C-terminal A prior to gel electrophoresis. Ligand dissociation was assayed by incubating cells in binding buffer with the unlabeled ligand (400 ng/ml) portions of the receptors were used for Western blot analysis. The rabbit antisera were directed against 14 amino acid long synthetic peptides in the presence or absence of the indicated Fab fragments (20 μg/ml) for various periods of time at 4°C. Non-specific binding and release of corresponding to the carboxy-terminal sequences of the respective human receptors. mAbs L26, L140 and L431 against the extracellular part of radiolabeled ligand were determined in parallel and subtracted from the total amount of bound ligand at each time point. human ErbB-2 have been described previously (Klapper et al., 1997) . Fab antibody fragments were prepared by the standard papain digestion procedure and separated from Fc fragments by passing over a column Lysate preparation, immunoprecipitation and Western blotting of an immobilized protein A. A monoclonal anti-phosphotyrosine antibody (PY-20, Santa Cruz Biotechnology) was used for Western blot For analysis of total cell lysates, gel sample buffer was added directly to cell monolayers or suspensions. For other experiments, solubilization analysis. An affinity-purified rabbit anti-mouse IgG was obtained from Jackson ImmunoResearch Laboratories. Goat-anti-human Fc antibodies buffer was added to cells on ice. Cells were scraped with a rubber policeman into 1 ml of buffer, transferred to microtubes, mixed harshly were purchased from Sigma. Surface plasmon resonance reagents including CM5 sensor chips, HEPES-buffered saline (HBS) containing 25 mM and centrifuged (10 000 g, 10 min at 4°C). Rabbit antibodies were coupled directly to protein A-Sepharose beads while shaking for 20 min. HEPES pH 7.4, 150 mM NaCl and 0.05% (w/v) P20 surfactant, N-hydroxysuccinimide (NHS), carMouse antibodies were first coupled to rabbit anti-mouse IgG and then to protein A-Sepharose beads. The proteins in the lysate supernatants bodiimide (EDC) 2-(2-pyridinyldithio)ethanamine hydrochloride and ethanolamine hydrochloride were obtained from Pharmacia Biotech. The were immunoprecipitated with aliquots of the protein A-Sepharoseantibody complex for 1 h at 4°C. Immunoprecipitates were then washed compositions of buffered solutions were described in Tzahar et al. (1996) . three times with HNTG (1 ml each wash) prior to heating (5 min at 95°C) in gel sample buffer. Samples were resolved by gel electrophoresis Establishment of ErbB-expressing cell lines CHO cells were transfected with mammalian expression vectors that through 7.5% acrylamide gels and electrophoretically transferred to nitrocellulose membranes. Membranes were blocked for 2 h in TBST direct expression of erbB-2 and erbB-3 cDNAs or with combinations of two receptor cDNAs as we previously described (Tzahar et al., 1996) . buffer (0.02 Tris-HCl buffered at pH 7.5, 0.15 M NaCl and 0.05% Tween-20) containing 1% milk, blotted with 1 μg/ml primary antibodies The 32D murine hematopoietic progenitor cell line expressing the various ErbB proteins was described previously (Pinkas-Kramarski et al., 1996a) . for 2 h, followed by 0.5 μg/ml secondary antibody linked to horseradish peroxidase. Immunoreactive bands were detected with an enhanced The cells were grown in RPMI-1640 medium supplemented with antibiotics, 10% heat-inactivated fetal bovine serum and 0.1% medium chemiluminescence reagent (Amersham Corp.). that was conditioned by an IL-3-producing cell line. The deletion mutant of ErbB-3 (denoted ErbB-3M) has been described previously (Tzahar Construction and expression of secreted soluble receptors To construct fused cDNAs between ErbBs and human immunoglobulin et al., 1996) . Other mutants were generated as follows. A polymerase chain reaction (PCR)-based strategy was used (Aiyar and Leis, 1993) to G 1 , we used the expression vector CDM7 (Invitrogen) coding for the extracellular portion of ErbB-1 fused in-frame to the Fc-coding portion amplify a DNA fragment coding for the extracellular domain of ErbB-3 or the transmembrane domain of the human FGFR3. Two PCR reactions (hinge, CH2 and CH3) of a human immunoglobulin γ-1 cDNA (denoted CDM7-IgB-1, kindly provided by G.Plowman). Construction of a similar were performed. In the first, ErbB-3M/pCDNA3 vector was used as a template and in the second reaction FGFR3/pCDNA3 vector was used.
fusion with erbB-2 (IgB-2) was done as follows: the CDM7-IgB-1 plasmid was digested with BamHI and HindIII to allow fusion of cDNAs The two PCR products overlapping over a stretch of 30 nucleotides were purified and subjected to a third PCR reaction using the external corresponding to Fc and the extracellular domain of ErbB-2. The extracellular domain-coding sequence of erbB-2 was amplified by PCR primers, thus generating an in-frame fusion between the extracellular domain of ErbB-3 and the transmembrane domain of FGFR3. The (30 cycles of 1.5 min at 96°C, 2 min at 52°C and 3 min at 72°C), purified, digested with BclI and HindIII and inserted to the appropriate amplified fragment was subcloned in-frame to a DNA segment encoding an 11 amino acid long Myc-tagged tail (followed by a stop codon). For sites in the expression vector. The upstream and downstream oligonucleotide primers of erbB-2 had the following respective sequences: 5Ј-GCCthis, a Kpn2I unique site within the sequence coding for the extracellular domain of ErbB-3M/pCDNA3 vector was used. An ErbB-3GPI fusion GGGAAGCTTGTGAGCACCATGGAGCTGGCG-3Ј and 5Ј-GCCGC-GCGTGATCAGGGCTGGCTCTCTGCTCGGC-3Ј. The different clonprotein encoding the ErbB-3 ectodomain and the C-terminal 37 amino acids of rat contactin (a gift from Elior Peles), that signals attachment ing sites are underlined. Nucleotide sequencing confirmed the integrity of the open reading frames of the chimeric cDNA and partially verified of a GPI anchor, was constructed in the same manner. In order to confirm the existence of a GPI anchor, cells were treated with PI-PLC (Sigma) correct sequences. Construction and purification of IgB-3 and IgB-4 were described previously . at 1 U/ml for 4 h at 37°C.
Radiolabeling of ligands, covalent cross-linking and
Biacore experiments and data analysis Human NDF, or IFN-γ as a control ligand, were cross-linked to the ligand-binding analyses Human recombinant-EGF, NDF-β1 177-246 or HB-EGF were labeled with hydrogel matrix of the biosensor using the NHS/EDC coupling procedure as previously described (Zhou et al., 1993) . The various ligands were Iodogen (Pierce) as described (Karunagaran et al., 1995) . The range of specific activity varied between 1ϫ10 5 and 1ϫ10 6 c.p.m./ng. For injected at 50-100 μg/ml in 10 mM sodium acetate buffers at pH values of 4.5-5.0. This procedure ensured immobilization of a gradient of NDF covalent cross-linking analysis, monolayers (10 7 cells) of cells were incubated on ice for 2 h with either [ 125 I]EGF (10 ng/ml) or [ 125 I]NDFconcentrations resulting in signals ranging from 500 to 2000 resonance units (RUs) in the various flow cells, or 700 RU for IFN-γ. Immobilized β1 (10 ng/ml). The chemical cross-linking reagent BS 3 was then added (1 mM) and, after 45 min on ice, cells were washed with phosphateligands could be regenerated over 30 cycles with a pulse of 100 mM glycine (pH 2.5) for 1 min at 10 μl/min. All the kinetics measurements buffered saline (PBS). To detect affinity labeling of ErbB-2, the assay was sensitized by scraping cells into 1 ml of PBS, concentrating them were performed in HBS at 25°C. Five serial dilutions of purified IgB proteins ranging from 5 to 900 nM, or conditioned media from HEKby centrifugation and then adding a relatively high concentration of radiolabeled NDF (100 ng/ml). After 1 h at 37°C, BS 3 was added and 293 cells that express the corresponding IgB proteins, were injected for 4 min and then washed for 12 min prior to regeneration. The flow rate cells incubated further for 30 min at 22°C. For ligand-binding analyses of 32D cells, 10 6 cells were washed once with binding buffer, and then was maintained at 20 μl/min to minimize mass transport effects. Nonspecific binding was derived from the binding of IgB proteins to incubated for 2 h at 4°C with a radiolabeled ligand (5 ng/ml) and various concentrations of an unlabeled ligand in a final volume of 0.2 ml. Nonimmobilized IFN-γ. To minimize the effect of potential rebinding, dissociation rate constants were derived from the kinetics of release specific binding was determined in the presence of a 100-fold molar excess of the unlabeled ligand. To terminate ligand binding, each reaction during the first 10 min of buffer flow. Data analysis and calculation of kinetic constants from the sensograms were performed using the tube was washed once with 0.5 ml of binding buffer and loaded on top of a 0.7 ml cushion of bovine serum. The tubes were spun (12 000 g, BIAcore software. 2 min) in order to remove the unbound ligand. Affinity labeling of soluble ErbB proteins was performed by incubating a radiolabeled Cell proliferation assays Cells were washed free of IL-3, resuspended in RPMI-1640 medium at ligand (30 ng/ml, 2ϫ10 5 c.p.m./ng) with 1 ml of serum-free medium, conditioned by cells expressing the various soluble receptors. After 1 h 5ϫ10 5 cells/ml and treated with or without EGF, NDF-β1 or biregulin at 100 ng/ml or IL-3 (1:1000 dilution of conditioned medium). Cell at 23°C, BS 3 (1 mM) was added and incubation proceeded for 30 min. Covalent complexes were adsorbed to an agarose-immobilized protein survival was determined by using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl] tetrazolium bromide (MTT) assay as previously described Groenen,L.C., Nice,E.C. and Burgess,A.W. (1994) 
